** Genetics testing firm Tempus AI's shares TEM.O fall 8.2% to $67.75
** Stifel cuts to "hold" from "buy"; raises price target to $65 from $45
** Brokerage says the valuation of stock looks stretched, after company commentary suggested 2025 outlook for core business might be guided below Street expectations
** Brokerage says co's acquisition of Ambry Genetics will be positive to overall business
** But it expects TEM's revenue growth to slow, especially in the data segment; points to the slower growth profile of Ambry's hereditary cancer testing market
** Avg rating of brokerages is a "buy"; median PT is $52 - LSEG data
** As of last close, TEM has risen 84.3% since its June 14 debut on Nasdaq
(Reporting by Sukriti Gupta in Bengaluru)
((Sukriti.Gupta@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.